H. Steve Zhang
Sangamo BioSciences
27 Papers
464 Citations
H. Steve Zhang is an academic researcher from Sangamo BioSciences. The author has contributed to research in topics: Zinc finger & Zinc finger nuclease. The author has an hindex of 13, co-authored 27 publications.
Chat about Author
Papers
A TALE nuclease architecture for efficient genome editing
Jeffrey C. Miller,Siyuan Tan,Guijuan Qiao,Kyle A. Barlow,Jianbin Wang,Danny F Xia,Xiangdong Meng,David Paschon,Elo Leung,Sarah J. Hinkley,Gladys P Dulay,Kevin Hua,Irina Ankoudinova,Gregory J. Cost,Fyodor D. Urnov,H. Steve Zhang,Michael C. Holmes,Lei Zhang,Philip D. Gregory,Edward J. Rebar +19 more
TL;DR: This study identifies TALE truncation variants that efficiently cleave DNA when linked to the catalytic domain of FokI and uses them to generate discrete edits or small deletions within endogenous human NTF3 and CCR5 genes at efficiencies of up to 25%.
2.4K
Genome editing with engineered zinc finger nucleases
TL;DR: A broad range of outcomes has resulted from the application of the same core technology: targeted genome cleavage by engineered, sequence-specific zinc finger nucleases followed by gene modification during subsequent repair.
Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations
Frank Soldner,Josee Laganiere,Albert W. Cheng,Dirk Hockemeyer,Qing Gao,Raaji Alagappan,Vikram Khurana,Vikram Khurana,Lawrence I. Golbe,Richard H. Myers,Susan Lindquist,Lei Zhang,Dmitry Guschin,Lauren K. Fong,B. Joseph Vu,Xiangdong Meng,Fyodor D. Urnov,Edward J. Rebar,Philip D. Gregory,H. Steve Zhang,Rudolf Jaenisch +20 more
TL;DR: In this article, the authors proposed to generate sets of isogenic disease and control human pluripotent stem cells that differ exclusively at either of two susceptibility variants for Parkinson's disease by modifying the underlying point mutations in the α-synuclein gene.
801
LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.
Laurie H. Sanders,Josee Laganiere,Oliver Cooper,Sally K. Mak,B. Joseph Vu,Y. Anne Huang,David Paschon,Malini Vangipuram,Ramya Sundararajan,Fyodor D. Urnov,J. William Langston,Philip D. Gregory,H. Steve Zhang,J. Timothy Greenamyre,Ole Isacson,Birgitt Schüle +15 more
TL;DR: After zinc finger nuclease-mediated repair of the LRRK2 G2019S mutation in iPSCs, mtDNA damage was no longer detected in differentiated neuroprogenitor and neural cells.
279
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease
Bryan Zeitler,Steven Froelich,Kimberly Marlen,David A. Shivak,Qi Yu,Davis Li,Jocelynn R. Pearl,Jeffrey C. Miller,Lei Zhang,David Paschon,Sarah J. Hinkley,Irina Ankoudinova,Stephen Lam,Dmitry Guschin,Lexi Kopan,Jennifer M. Cherone,Hoang Oanh B. Nguyen,Guijuan Qiao,Yasaman Ataei,Matthew C. Mendel,Rainier Amora,Richard T. Surosky,Josee Laganiere,B. Joseph Vu,Anand Narayanan,Yalda Sedaghat,Karsten Tillack,Christina Thiede,Annette Gärtner,Seung Kwak,Jonathan Bard,Ladislav Mrzljak,Larry Park,Taneli Heikkinen,Kimmo Lehtimäki,Marie Svedberg,Jenny Haggkvist,Lenke Tari,Miklós Tóth,Andrea Varrone,Christer Halldin,Andrea E. Kudwa,Sylvie Ramboz,Michelle Day,Jyothisri Kondapalli,D. James Surmeier,Fyodor D. Urnov,Philip D. Gregory,Edward J. Rebar,Ignacio Munoz-Sanjuan,H. Steve Zhang +50 more
TL;DR: Improvements in a range of molecular, histopathological, electrophysiological and functional endpoints are demonstrated and support the continued development of an allele-selective ZFP-TF for the treatment of Huntington’s disease.
187